ABSTRACT
The rationale for gonadotropin-releasing hormone (GnRH) agonist therapy in pediatrics is based on the ability of these compounds to reduce gonadal function, halting the pubertal process. Uses of GnRH agonist in pediatrics include:
(1) The treatment of central precocious puberty (CPP) to halt puberty;
(2) The treatment of short-statured children with normal puberty to provide additional time for prepubertal linear growth;
(3) The provision of gonadal protection during chemotherapy.
